Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for some types of allergies. It is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an attempt to change the immune system's response.
The primary therapeutic goals of allergy immunotherapy (AIT) include reducing symptoms, reducing symptomatic medication use, and improving allergyrelated quality of life. The evidence is strong that AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation.
Scope of the Report:
The classification of Allergy Immunotherapy includes Subcutaneous Immunotherapy and Sublingual Immunotherapy. The proportion of Subcutaneous Immunotherapy in 2017 is about 55.1%, and the proportion of Sublingual Immunotherapy in 2016 is about 44.9%.
Allergy Immunotherapy are application in Allergic Rhinitis, Allergic Asthma and Other. The most of Allergy Immunotherapy is used in Allergic Rhinitis, and the market share of that is about 45.3 % in 2017.
Europe is the largest consumption place, with a consumption market share nearly 68.5% in 2017, Allergy is the most common chronic disease in Europe. Up to 20% of patients with allergies struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction. Following Europe, North America is the second largest consumption place with the consumption market share of 19.2% in 2017. Allergy Immunotherapy market in Asia Pacific region is expected to exhibit the highest growth rate due to high incidence of allergy people in the developing Asian countries like China & India.
Market competition is intense. ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, etc. are the leaders of the industry with the market share is about 76.6% in 2017.
The global Allergy Immunotherapies (Allergy Immunotherapy) market is valued at 1070 million USD in 2018 and is expected to reach 1890 million USD by the end of 2024, growing at a CAGR of 9.9% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Allergy Immunotherapies (Allergy Immunotherapy).
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Allergy Immunotherapies (Allergy Immunotherapy) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Allergy Immunotherapies (Allergy Immunotherapy) market by product type and applications/end industries.
Market Segment by Companies, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into